^
IDH2 mutation
GBM
AV-GBM-1
Sensitive: C3 – Early Trials
SITC 2021 - 3 weeks
IDH1 mutation
GBM
AV-GBM-1
Sensitive: C3 – Early Trials
SITC 2021 - 3 weeks
MGMT promoter methylation
GBM
AV-GBM-1
Sensitive: C3 – Early Trials
SITC 2021 - 3 weeks
No biomarker
GBM
Byvasda (bevacizumab biosimilar)
Sensitive: A1 - Approval
No biomarker
GBM
bevacizumab
Sensitive: A1 - Approval
No biomarker
GBM
temozolomide
Sensitive: A1 - Approval
No biomarker
GBM
carmustine
Sensitive: A1 - Approval
No biomarker
GBM
Zirabev (bevacizumab biosimilar)
Sensitive: A1 - Approval
No biomarker
GBM
Mvasi (bevacizumab biosimilar)
Sensitive: A1 - Approval
No biomarker
GBM
Krabeva (bevacizumab biosimilar)
Sensitive: A1 - Approval
BRAF V600E
GBM
trametinib + dabrafenib
Sensitive: A2 - Guideline
No biomarker
GBM
PCV
Sensitive: A2 - Guideline
MGMT promoter methylation
GBM
temozolomide
Sensitive: A2 - Guideline
No biomarker
GBM
lomustine
Sensitive: A2 - Guideline
No biomarker
GBM
regorafenib
Sensitive: A2 - Guideline
BRAF V600E
GBM
vemurafenib + cobimetinib
Sensitive: A2 - Guideline
NTRK3 fusion
GBM
entrectinib
Sensitive: A2 - Guideline
NTRK1 fusion
GBM
larotrectinib
Sensitive: A2 - Guideline
NTRK3 fusion
GBM
larotrectinib
Sensitive: A2 - Guideline
NTRK2 fusion
GBM
larotrectinib
Sensitive: A2 - Guideline
NTRK1 fusion
GBM
entrectinib
Sensitive: A2 - Guideline
NTRK2 fusion
GBM
entrectinib
Sensitive: A2 - Guideline
No biomarker
GBM
VAL-083
Sensitive: B - Late Trials
No biomarker
GBM
enzastaurin
Sensitive: B - Late Trials
No biomarker
GBM
DNX-2401
Sensitive: B - Late Trials
No biomarker
GBM
GDC-0084
Sensitive: B - Late Trials
MGMT unmethylation
GBM
temozolomide
Sensitive: B - Late Trials
No biomarker
GBM
GLR2007
Sensitive: B - Late Trials
No biomarker
GBM
VB-111
Sensitive: B - Late Trials
No biomarker
GBM
CYNK-001
Sensitive: B - Late Trials
No biomarker
GBM
VBI-1901
Sensitive: B - Late Trials
No biomarker
GBM
RTA 744
Sensitive: B - Late Trials
BRAF V600E
GBM
vemurafenib
Sensitive: C1 - Off-label
MSI-H/dMMR
GBM
nivolumab
Sensitive: C1 - Off-label
BRAF V600
GBM
vemurafenib
Sensitive: C1 - Off-label
BRAF V600E
GBM
dabrafenib
Sensitive: C1 - Off-label
EGFR mutation
GBM
erlotinib
Sensitive: C1 - Off-label
PD-L1 expression
GBM
pembrolizumab
Sensitive: C1 - Off-label
VHL mutation
GBM
belzutifan
Sensitive: C1 - Off-label
EGFR amplification
GBM
ABT-414
Sensitive: C2 – Inclusion Criteria
IDH1 mutation
GBM
temozolomide
Sensitive: C2 – Inclusion Criteria
EGFR mutation
GBM
verteporfin
Sensitive: C2 – Inclusion Criteria
EGFR amplification
GBM
lapatinib
Sensitive: C2 – Inclusion Criteria
IDH1 mutation
GBM
NEO100
Sensitive: C2 – Inclusion Criteria
EGFR amplification
GBM
KD019
Sensitive: C2 – Inclusion Criteria
PTEN mutation
GBM
atezolizumab + GDC-0068
Sensitive: C3 – Early Trials
MIF overexpression
GBM
aflibercept intravitreal
Sensitive: C3 – Early Trials
miR-30b-3p underexpression
GBM
temozolomide
Sensitive: C3 – Early Trials
MGMT underexpression
GBM
temozolomide
Sensitive: C3 – Early Trials
MGMT promoter methylation
GBM
cilengitide
Sensitive: C3 – Early Trials
FGFR3-TACC3 fusion
GBM
anlotinib
Sensitive: C3 – Early Trials
MGMT unmethylation
GBM
nivolumab + ipilimumab
Sensitive: C3 – Early Trials
MGMT unmethylation
GBM
cemiplimab + INO-5401 + INO-9012
Sensitive: C3 – Early Trials
FLT1 elevation
GBM
pembrolizumab
Resistant: C3 – Early Trials
PIGF elevation
GBM
pembrolizumab
Resistant: C3 – Early Trials
MGMT unmethylation
GBM
VAL-083
Sensitive: C3 – Early Trials
MGMT unmethylation
GBM
pembrolizumab
Resistant: C3 – Early Trials
IDH1 mutation
GBM
pembrolizumab
Resistant: C3 – Early Trials
VEGFA elevation
GBM
pembrolizumab + bevacizumab
Resistant: C3 – Early Trials
FLT1 overexpression
GBM
pembrolizumab + bevacizumab
Resistant: C3 – Early Trials
FLT1 overexpression
GBM
pembrolizumab
Resistant: C3 – Early Trials
PIGF overexpression
GBM
pembrolizumab + bevacizumab
Resistant: C3 – Early Trials
PIGF overexpression
GBM
pembrolizumab
Resistant: C3 – Early Trials
CD47 overexpression
GBM
VT1021
Sensitive: C3 – Early Trials
PLK2 underexpression
GBM
temozolomide
Resistant: C3 – Early Trials
TERT 124C>T
GBM
PD1 inhibitor
Sensitive: C3 – Early Trials
TMB-L
GBM
PD1 inhibitor
Sensitive: C3 – Early Trials
CD36 overexpression
GBM
VT1021
Sensitive: C3 – Early Trials
MGMT unmethylation
GBM
NOX-A12
Sensitive: C3 – Early Trials
BRAF V600E
GBM
BRAF inhibitor + MEK inhibitor
Sensitive: C3 – Early Trials
PIK3CA mutation + TTN mutation + IDH2 mutation + Chr del(1q) + Chr del(17)
GBM
temozolomide
Sensitive: C3 – Early Trials
IDH2 mutation + MGMT promoter methylation
GBM
temozolomide
Sensitive: C3 – Early Trials
IDH1 mutation + MGMT promoter methylation
GBM
temozolomide
Sensitive: C3 – Early Trials
HLA-DQA1 overexpression
GBM
bevacizumab
Sensitive: C3 – Early Trials
AGT underexpression
GBM
bevacizumab
Sensitive: C3 – Early Trials
BICD1 overexpression
GBM
temozolomide
Resistant: C3 – Early Trials
IDH2 mutation
GBM
temozolomide gel
Sensitive: C3 – Early Trials
SETD2 mutation + MGMT promoter methylation
GBM
temozolomide gel
Resistant: C3 – Early Trials
KDR overexpression
GBM
bevacizumab + erlotinib
Resistant: C3 – Early Trials
EPAS1 overexpression
GBM
bevacizumab + erlotinib
Resistant: C3 – Early Trials
CCL27 overexpression
GBM
aflibercept intravitreal
Sensitive: C3 – Early Trials
PIGF-L
GBM
aflibercept intravitreal
Sensitive: C3 – Early Trials
CXCL10 overexpression
GBM
aflibercept intravitreal
Sensitive: C3 – Early Trials
TMB-H
GBM
Immunotherapy
Sensitive: C3 – Early Trials
RB1 expression
GBM
palbociclib
Resistant: C3 – Early Trials
TERT mutation + MGMT promoter methylation
GBM
temozolomide
Resistant: C3 – Early Trials
EGFRVIII expression + PTEN expression
GBM
EGFR inhibitor
Sensitive: C3 – Early Trials
EGFRVIII expression + PTEN expression
GBM
erlotinib
Resistant: C3 – Early Trials
EGFR amplification
GBM
erlotinib
Resistant: C3 – Early Trials
FGFR3-TACC3 fusion
GBM
erdafitinib
Sensitive: C3 – Early Trials
EGFRvIII mutation
GBM
erlotinib
Resistant: C3 – Early Trials
TNFA overexpression
GBM
bevacizumab
Resistant: C3 – Early Trials
MET overexpression + KDR overexpression
GBM
bevacizumab
Resistant: C3 – Early Trials
KDR overexpression
GBM
bevacizumab
Resistant: C3 – Early Trials
MET overexpression
GBM
bevacizumab
Resistant: C3 – Early Trials